AI Article Synopsis
- In 2014, Sweden implemented managed entry agreements (MEAs) to improve access to treatments by enabling negotiations between health care payers, a reimbursement authority, and pharmaceutical companies.
- The study aimed to evaluate these agreements from January 2015 to August 2019, focusing on the types of uncertainties addressed and investigating the incentives created in Sweden's performance-based reimbursement schemes.
- Findings indicated that 56 products had agreements, primarily in hepatitis C and oncology, with ongoing uncertainties related to patient population size, treatment duration, and effectiveness, highlighting that affordability was the main concern rather than uncertainty management.
Article Abstract
Background: In 2014 managed entry agreements (MEA) between Swedish health care payers (county councils), the reimbursement authority (the Dental and Pharmaceutical Benefits Agency (TLV)) and pharmaceutical companies were introduced to facilitate early and equal access to treatments. MEAs complement the value-based pricing system for out-patient drugs and enables stake-holders to negotiate risk-sharing agreements.
Aim: The aim of the study was to review existing agreements, describe the type of uncertainty dealt with, and to analyze incentives created using the literature on performance-based reimbursement schemes in Sweden.
Method: A document review of all agreements made in the period January 2015 to August 2019 was conducted, classifying agreements by the type of uncertainty dealt with.
Results: Agreements were made for 56 products during the studied time period (45 ongoing), mainly in the fields of hepatitis C (n = 10) and oncology (n = 14). Uncertainties addressed in ongoing agreements included size of treated population (10), treatment duration (13), and effectiveness (9). The mechanism for risk-sharing was limited to refunds based on patient numbers, duration or just flat-rate refunds. The estimated refund in 2018 was 50 % of total sales.
Discussion: This review show that the main driver behind risk sharing in Sweden so far have seem to be affordability rather than managing uncertainty.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.healthpol.2020.02.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Grouping of chemicals for safety assessment: the importance of toxicokinetic properties of salicylate esters.
Arch Toxicol
January 2025
Cosmetics Europe, Brussels, Belgium.
Grouping of chemicals has been proposed as a strategy to speed up the screening and identification of potential substances of concern among the broad chemical universe under REACH. Such grouping is usually based on shared structural features and should only be used for the prioritization objectives. However, additional considerations (as well as structural similarity) are needed, e.
View Article and Find Full Text PDFA genetic exploration of the relationship between posttraumatic stress disorder and cardiovascular diseases.
Transl Psychiatry
January 2025
Genetic Epidemiology Group, Department of Psychiatry, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Experiencing a traumatic event may lead to Posttraumatic Stress Disorder (PTSD), including symptoms such as flashbacks and hyperarousal. Individuals suffering from PTSD are at increased risk of cardiovascular disease (CVD), but it is unclear why. This study assesses shared genetic liability and potential causal pathways between PTSD and CVD.
View Article and Find Full Text PDFSuccessful thoracoscopic-assisted resection of a functional paraganglioma in the mediastinum with extracorporeal circulation: a case report.
J Cardiothorac Surg
January 2025
Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P. R. China.
Background: Paragangliomas are rare neoplasms arising from extra-adrenal chromaffin cells, with mediastinal paragangliomas representing an exceptionally rare subset. This report details the surgical management of a complex mediastinal paraganglioma case, presenting with refractory hypertension and invasion of critical surrounding structures. A comprehensive review of the current literature is included to underscore existing cases, enhance clinical awareness, and share our insights and experience in the diagnosis and treatment of this challenging condition.
View Article and Find Full Text PDFExploring policy processes against microbial threats in Iran: a qualitative policy analysis.
BMJ Open
January 2025
Department of Environmental Health Engineering, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran (the Islamic Republic of).
Objectives: Microbial threats pose a growing concern worldwide. This paper reports the analysis of Iran's policy process against microbial threats.
Design: This is a qualitative study.
Identification of potential therapeutic targets for Alzheimer's disease from the proteomes of plasma and cerebrospinal fluid in a multicenter Mendelian randomization study.
Int J Biol Macromol
January 2025
First Operating Room, The First Hospital of Jilin University, Changchun, China. Electronic address:
Background: Certain peripheral proteins are believed to be involved in the development of Alzheimer's disease (AD), but the roles of other new protein biomarkers are still unclear. Current treatments aim to manage symptoms, but they are not effective in stopping the progression of the disease. New drug targets are needed to prevent Alzheimer's disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!